» Articles » PMID: 18618663

Striatal Dopamine Transporter Imaging Correlates with Depressive Symptoms and Tower of London Task Performance in Parkinson's Disease

Overview
Journal Mov Disord
Date 2008 Jul 12
PMID 18618663
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

We studied whether the (123)I-FP-CIT uptake in the striatum correlates with depressive symptoms and cognitive performance in patients with Parkinson's disease (PD). Twenty patients with PD without major depression and/or dementia (mean age 61.7 +/- 12.7 years) underwent the (123)I-FP-CIT SPECT. Depressive symptoms and cognitive performance were assessed in the ON state. The ratios of striatal to occipital binding for the entire striatum, putamina, and putamen to the caudate (put/caud) index were calculated in the basal ganglia. The association between neuropsychiatric measures and dopamine transporter (DAT) availability was calculated; multiple regression analysis was used to assess association with age and disease duration. We found significant correlations between Montgomery and Asberg Depression Rating Scale (MARDS) and Tower of London (TOL) task scores and (123)I-FP-CIT uptake in various striatal ROIs. Multiple regression analysis confirmed the significant relationship between TOL performance and put/caud ratio (P = 0.001) and to age (P = 0.001), and between MADRS and left striatal (P = 0.005) and putaminal DAT availability (P = 0.003). Our pilot study results demonstrate that imaging with (123)I-FP-CIT SPECT appears to be sensitive for detecting dopaminergic deficit associated with mild depressive symptoms and specific cognitive dysfunction in patients with PD, yet without a current depressive episode and/or dementia.

Citing Articles

The pathobiological basis of depression in Parkinson disease: challenges and outlooks.

Jellinger K J Neural Transm (Vienna). 2022; 129(12):1397-1418.

PMID: 36322206 PMC: 9628588. DOI: 10.1007/s00702-022-02559-5.


Depression in Patients with Parkinson's Disease: Current Understanding of its Neurobiology and Implications for Treatment.

Prange S, Klinger H, Laurencin C, Danaila T, Thobois S Drugs Aging. 2022; 39(6):417-439.

PMID: 35705848 PMC: 9200562. DOI: 10.1007/s40266-022-00942-1.


Depression history modulates effects of subthalamic nucleus topography on neuropsychological outcomes of deep brain stimulation for Parkinson's disease.

Kratter I, Jorge A, Feyder M, Whiteman A, Chang Y, Henry L Transl Psychiatry. 2022; 12(1):213.

PMID: 35624103 PMC: 9142573. DOI: 10.1038/s41398-022-01978-y.


Analyzing Complex Problem Solving by Dynamic Brain Networks.

Alchihabi A, Ekmekci O, Kivilcim B, Newman S, Yarman Vural F Front Neuroinform. 2021; 15:670052.

PMID: 34955799 PMC: 8705227. DOI: 10.3389/fninf.2021.670052.


Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinson's disease: clues to early diagnosis and effective treatment.

Bang Y, Lim J, Choi H Arch Pharm Res. 2021; 44(6):588-604.

PMID: 34145553 PMC: 8254697. DOI: 10.1007/s12272-021-01337-3.